prucalopride / Generic mfg. - LARVOL DELTA

Comparative Efficacy of Pharmacologic Therapies for Gastroparesis: A Systematic Review and Network Meta-Analysis (ACG 2025) - "Interventions included prucalopride, cisapride, revexepride, metoclopramide, relamorelin, TZP-102, aprepitant, tradipitant, cannabidiol (CBD), and domperidone. A total of 21 trials comprising 2,452 patients were included in the study. For symptom improvement, 19 studies that compared 10 treatments contributed to the network. Cisapride (SMD, 1.88; 95% CI –2.71 to –1.06; SUCRA=0.98), relamorelin (SMD, 1.15; 95% CI –2.15 to –0.16; SUCRA=0.86), and aprepitant (SMD: 0.60; 95% CI –0.88 –0.32; SUCRA=0.76) significantly outperformed the placebo."

Retrospective data • Review • Gastrointestinal Disorder

AMYOTROPHIC LATERAL SCLEROSIS CAUSING COLONIC DYSMOTILITY (CHEST 2025) - "The patient was started on riluzole...He was tried on neostigmine, pyridostigmine, and prucalopride without significant improvement... The mechanism of gastrointestinal dysfunction in ALS is unclear however, it is likely due to dysautonomia. This appears to be an under-recognized aspect of the disease. Management of the gastrointestinal problems itself as well as treatment of the underlying disease can lead to favorable outcomes."

Amyotrophic Lateral Sclerosis • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Respiratory Diseases

CHRONIC INTESTINAL PSEUDO-OBSTRUCTION IN A PATIENT WITH ANTI-EJ ANTISYNTHETASE SYNDROME (UEGW 2025) - "The patient's immunosuppressive therapy was escalated to tofacitinib and supportive treatment with prokinetics (prucalopride), non- absorbable antibiotics for small intestinal bacterial overgrowth and nutritional supplementation, was initiated. The treatment of CIPO involves two main approaches: addressing the underlying disease, in this particular case, through immunosuppression, and providing supportive care to maintain adequate nutrition. A high index of suspicion for severe GI motility disorders is essential to avoid delays in diagnosis and to initiate effective treatment promptly."

Clinical • Gastrointestinal Disorder • Immunology • Myositis • Rare Diseases • Rheumatology

THE FRENCH CONSENSUS ON IDIOPATHIC GASTROPARESIS IN ADULTS AND CHILDREN (UEGW 2025) - "A blood test and screening for Helicobacter pylori were supported before diagnosing IG.Regarding the management, like in recent guidelines, the panel supported a first-line therapy using dietary advice and dopamine antagonists (metoclopramide or domperidone). The panel supported the efficacy of intravenous erythromycin, but not oral erythromycin. Agreement on the efficacy of other drugs, including prucalopride, antiemetics, or neuromodulators, was not reached... This consensus shows that the diagnostic modalities for IG are similar in France as compared to international guidelines, but highlights differences in the management of refractory gastroparesis, supporting endoscopic pyloromyotomy or the implantation of gastric electrical stimulation."

Clinical • Constipation • Gastrointestinal Disorder • Infectious Disease • Pediatrics

MULTICENTRE EVALUATION OF THE OMOM COLON CAPSULE: REAL-WORLD PERFORMANCE AND REMOTE NURSE-LED PROCEDURE ACROSS FOUR EUROPEAN CENTRES (UEGW 2025) - "Bowel preparation protocol included laxatives, boosters and prucalopride (where available)... The OMOM CC system demonstrated robust diagnostic performance and high patient acceptability in a real-world, multinational cohort. High pathology detection rates in both small bowel and colon, particularly among patients with prior incomplete colonoscopy. A remote procedure model with centralized interpretation by trained readers supports scalable integration into pathways for lower GI diagnostics."

Clinical • Real-world • Real-world evidence • Anemia • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease

INTERNATIONAL CONSENSUS ON CHRONIC INTESTINAL PSEUDO-OBSTRUCTION IN ADULTS (UEGW 2025) - "There was no consensus regarding choice or efficacy of drug therapy, including prokinetics (e.g. pyridostigmine, prucalopride), laxatives, or somatostatin analogs... This expert consensus developed key statements for the definition, diagnosis, and treatment of CIPO in adult patients. It provides the opportunity to harmonize the management of these patients and to highlight the gaps in the current literature."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Osteoporosis • Rheumatology • Scleroderma • Systemic Sclerosis

OPTIMIZING CAPSULE ENDOSCOPY PATENCY TESTING: A NOVEL PROTOCOL USING GASTROGRAFIN, PRUCALOPRIDE, AND FASTING- A SINGLE CENTER EXPERIENCE (UEGW 2025) - "This pilot study shows that Gastrografin, fasting and Prucalopride is a promising regimen with a high pass rates in patients undergoing PC. This strategy is lucarative in centers which has limited access to CT post PC. Fasting then ingesting PC promotes the gastro-ileal reflex increasing GI motility."

Clinical

Effect of electroacupuncture versus prucalopride for ultra-severe chronic constipation: Secondary analysis of a randomized controlled trial. (PubMed, Integr Med Res) - P=N/A | "The effects of EA might persist for 24 weeks, and EA exhibited a superior safety profile. NCT02047045 (ClinicalTrials.gov)."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

An Intriguing Case of Hypermobile Ehlers-Danlos Syndrome Presenting With Severe Gut Dysmotility and Refractory Gastroparesis (ACG 2025) - "Full-thickness biopsy via laparoscopic gastric pacemaker placement revealed fibrosis of the myenteric plexus with sparse ganglion cells. Despite trials of metoclopramide, erythromycin, domperidone, and prucalopride, the patient exhibited minimal clinical improvement. Early recognition, combined with integrative care, is critical. As awareness of hEDS-related GI dysfunction grows, more systematic investigation is needed to inform targeted therapies and long-term outcomes."

Clinical • Fibrosis • Gastrointestinal Disorder • Genetic Disorders • Immunology • Rheumatology

Fast and Frequent: How Effective Is Prucalopride in Chronic Constipation? A Systematic Review and Meta-Analysis of Randomized Controlled Trial (ACG 2025) - "We included seven RCTs comprising 3,389 patients, of whom 2,020 were randomized to receive prucalopride. The mean age was 48.1 years, 76.1% were women, and the average duration of constipation was 16.1 years. Approximately 80% had an inadequate response to prior treatments, and 66% reported fewer than one bowel movement per week at baseline."

Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder

ALS Complicated with Ogilvie's Syndrome (ACG 2025) - "Riluzole 50 mg BID was started...He was managed with nasogastric suction, pyridostigmine 60 mg BID, and prucalopride, but symptoms persisted...Pyridostigmine was tried but showed limited effectiveness. Constipation in patients with ALS should be approached with caution, as it may indicate the development of Ogilvie syndrome."

Amyotrophic Lateral Sclerosis • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Inflammation • Movement Disorders • Muscle Spasticity

The Last Stand: Intravenous Immunoglobulin Treatment for Recurrent Pseudo-Obstruction Secondary to Scleroderma (ACG 2025) - "In the previous 6 months, he had 5 admissions for management of his PO despite trials of prucalopride and erythromycin. The use of IVIG in a few case reports has shown to assist with symptom improvement and weight gain, however, no formal study on its efficacy and impact on readmission exists. Our patient demonstrated a positive response to IVIG treatment and a reduction in readmission supporting its use for recurrent SSc PO.Figure: Figure 1: CT abdomen and pelvis with oral contrast demonstrating small bowel dilation with a focal narrowing in the distal ileum.Figure: Figure 2: X-ray of the abdomen demonstrating small bowel dilation with minimal passage of oral contrast into the colon prior to initiation of IVIG treatment (a) and with improved and stable PO post-IVIG treatment (b)."

Immunology • Inflammation • Rheumatology • Scleroderma • Systemic Sclerosis

Uncharted Territory: The Secretory Diarrhea Variant of Ogilvie's Syndrome (ACG 2025) - "Promotility agents like prucalopride and erythromycin have been successful in isolated case reports but were declined by him due to their adverse effects...He was discharged with a follow-up after hypokalemia resolved with spironolactone, octreotide, and daily potassium repletion. The secretory diarrhea variant of Ogilvie's syndrome is a rare disease...There are only a few case reports on this disease but no standard guidelines. This case seeks to help in the management of this disease through the use of aldosterone antagonists and somatostatin analogs.Figure: Computed tomography (CT) scan of the abdomen showing colonic dilatation without a transition point.Figure: Computed tomography (CT) scan of the abdomen showing colonic dilatation without a transition point."

Asthma • Cardiovascular • Chronic Kidney Disease • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Rare Diseases • Renal Disease • Respiratory Diseases

Uncommon Culprit: Sarcina Ventriculi Causing Gastric Ulceration in a Gastroparetic Patient (ACG 2025) - "She was given metoclopramide, rifaximin, and prucalopride with no relief...She was treated with nasogastric decompression which provided improvement and discharged on intranasal metoclopramide...Ultimately, while S.ventriculi may not be pathogenic in all cases, its detection, particularly in patients with gastroparesis should prompt physicians to consider antibiotic therapy and repeat biopsies. Growing recognition of this organism and its potential pathogenicity may hopefully lead to formalized treatment guidelines."

Clinical • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Respiratory Diseases

In Hot Water: Neurogastroenterology and Motility Sequelae of Cytoreductive Surgery (CRS) Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (ACG 2025) - "We present a case series of neurogastroenterology and motility sequelae in 3 patients with abdominal cancers and peritoneal metastasis who were treated with cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC).Case Description/ 58-year-old female with high grade appendiceal cancer underwent right hemicolectomy, peritonectomy, omentectomy + HIPEC (Mitomycin-C)...A diagnosis of chronic intestinal pseudo-obstruction (CIPO) was made and she was successfully treated with prucalopride and pyridostigmine.47-year-old female with stage IVB serous ovarian cancer underwent hysterectomy, bilateral salpingo-oophorectomy, peritonectomy, omentectomy and right hemicolectomy followed by adjuvant chemotherapy. PET/CT scan showed recurrent peritoneal metastases requiring secondary cytoreduction + HIPEC (cisplatin/paclitaxel)...Symptoms improved remarkably on pancreatic enzyme replacement therapy.76-year-old male with stage IV sigmoid colon cancer underwent..."

Surgery • Alopecia • Appendix Cancer • Colon Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Disorder • Gynecology • Immunology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Peritoneal Cancer • Solid Tumor

New Kid on the Block: Could Suzetrigine's Promise of Pain Relief Improve Outcomes in Management of DGBI? (ACG 2025) - "He tried linaclotide, plecanatide, lubiprostone, prucalopride, and tenapanor...Adjunct pharmacological neuromodulators like nortriptyline, duloxetine and gabapentin were not helpful...She responded partially to duloxetine, buspirone, mirtazapine, and cognitive behavioral therapy...Studies have directly and indirectly established the importance of NaV1.8 to visceral pain perception (Table 1). Additional trials are needed to evaluate the impact of this medicine on visceral pain perception especially in conditions associated with acute and/or chronic abdominal pain, including DGBIs.Figure: Summary of Studies Supporting the Role of Nav1.8 in Visceral Pain Perception"

Cardiovascular • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Mood Disorders • Novel Coronavirus Disease • Pain • Psychiatry • NAV1

Bowel Preparation Quality in Elderly vs Younger Adults: Implications for Colorectal Cancer Screening (ACG 2025) - "Adjunctive agents like simethicone and prucalopride also enhanced mucosal visibility. Physiological and logistical limitations restrict many elderly adults from achieving the necessary bowel preparation for colonoscopy. Among 3,436 elderly patients, bowel prep adequacy ranged from 65.4% to 81.1% and was significantly lower than younger cohorts (77.3%-94.4%). Common risk factors for poor prep included: male sex, type 2 diabetes, constipation, impaired mobility and lack of support. Mean BBPS scores were lower in the elderly patients: 6.3 vs 6.6."

Clinical • Alzheimer's Disease • Cognitive Disorders • Colorectal Cancer • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

A tale of two receptors: simultaneous targeting of NMDARs and 5-HT4Rs exerts additional effects against stress. (PubMed, Biol Psychiatry) - "Our results indicate that K+P has extended benefits, in comparison to K or P alone, for combating stress-induced pathophysiology at the behavioral and neural level. Our findings provide preliminary evidence that future studies using this combined treatment strategy may prove advantageous in protecting against a broader range of stress-induced psychiatric disorders."

Journal • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry • CA3 • FOS

Laxative logic: when lifestyle is not enough. (PubMed, Curr Opin Gastroenterol) - "Patients with constipation now have access to a wide range of medications, from over-the-counter osmotic and stimulant agents to prescription laxative combination strategies. This breadth allows clinicians to tailor therapy to diverse pathophysiology and symptom profiles. Yet despite this choice, real-world adherence remains poor and many patients are dissatisfied, reflecting the complexity of treating constipation and frequent mismatches between therapy and patients' most bothersome symptoms. Management should emphasize careful symptom assessment, shared decision-making, and clear expectation setting, while leveraging the available armamentarium."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Role of Prucalopride in the Treatment of Chronic Constipation in Parkinson's Disease: A Randomized Controlled Trial. (PubMed, Am J Gastroenterol) - "Prucalopride was safe, well-tolerated, and more effective than placebo in increasing bowel movement frequency in PD patients with chronic constipation, supporting its potential as a therapeutic option in this population."

Journal • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Movement Disorders • Parkinson's Disease

AGA Clinical Practice Guideline on Management of Gastroparesis. (PubMed, Gastroenterology) - "The diagnosis of gastroparesis requires the use of 4-hour gastric emptying tests. Metoclopramide or erythromycin is appropriate for initial pharmacologic treatment. Other treatment recommendations require shared patient-physician decision making. There are still considerable unmet needs in the treatment of gastroparesis."

Clinical guideline • Journal • Diabetes • Gastrointestinal Disorder • Metabolic Disorders

Effects on hippocampal activity following 5-HT4 receptor agonism in unmedicated patients with depression: the RESTAND study. (PubMed, medRxiv) - "In this double-blind, randomised study, 52 right-handed, unmedicated individuals with MDD received 6-9 days of the 5-HT 4 R agonist PF-04995274 (15mg, once daily) or placebo. This replicates and extends previous findings in healthy volunteers using prucalopride, and is consistent with preclinical evidence establishing a key role for 5-HT 4 Rs in hippocampal-dependent learning and memory. This translational evidence supports a role for 5-HT 4 R activation in modulating memory-related brain circuits in MDD and highlights its therapeutic potential for treating cognitive symptoms of depression."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

20 years of magnetic particle imaging - from patents to patients. (PubMed, Biochem Biophys Res Commun) - "The recent reintroduction of a clinically approved tracer (Resotran) and the emergence of human-scale scanners mark important steps toward clinical implementation. As the field moves forward, the validation of clinical benefit through prospective trials remains a key challenge. Nevertheless, current momentum strongly suggests that MPI is ready to become a valuable tool in clinical diagnostics within the near future."

Journal • Cardiovascular

Post-Marketing Study of Prucalopride Safety In Pregnancy (clinicaltrials.gov) - P=N/A | N=127 | Active, not recruiting | Sponsor: Takeda | Recruiting ➔ Active, not recruiting | N=616 ➔ 127 | Trial completion date: May 2026 ➔ Feb 2027 | Trial primary completion date: May 2026 ➔ Feb 2027

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Constipation • Gastroenterology • Gastrointestinal Disorder

Current Treatment Options for Children with Functional Constipation-What Is in the Pipeline? (PubMed, Children (Basel)) - "New agents such as lubiprostone, prucalopride, linaclotide, and plecanatide have demonstrated improved outcomes compared to placebo or conventional therapies, particularly in increasing spontaneous bowel movements. Therapy-resistant FC in children is a complex and impactful condition. An individualized, stepwise approach is essential, with surgical options such as colonic resection reserved as a last resort."

Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Pediatrics